Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
JCO Precision Oncology|June 12, 2026
Liquid Biopsy Monitoring in <i>BRAF</i> V600E-Mutated Patients With Non-Small Cell Lung Cancer Treated With Dabrafenib Plus Trametinib: The Prospective, Multicenter LiBRA Study (GOIRC-03-2020)Alessandro Leonetti, Monica Pluchino, Roberta Minari, et al.
Frontiers in Oncology|July 24, 2024
Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT studyMarco Sposito, Lorenzo Belluomini, Riccardo Nocini, et al.
Oncoimmunology|April 7, 2025
Surrogate markers of intestinal dysfunction associated with survival in advanced cancersRoxanne Birebent, Damien Drubay, Carolina Alves Costa Silva, et al.
Oncoimmunology|September 18, 2023
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patientsAnnalisa Adamo, Cristina Frusteri, Sara Pilotto, et al.
Frontiers in Oncology|March 4, 2026
Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational studyGiulia Pasello, Claudia Proto, Carlo Genova, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2025
A prospective study on clinicians' attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020)Francesco Facchinetti, Andrea Camerini, Chiara Bennati, et al.
Lung Cancer (Amsterdam, Netherlands)|September 30, 2025
Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS databaseMaria Lucia Reale, Daniela Scattolin, Antonio Vitale, et al.
Tumori|May 4, 2026
Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to <i>KRAS</i> status: An Italian real-world studyAlessandro Leonetti, Vanessa Callegari, Fabiana Perrone, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2024
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexedAlessandro Leonetti, Fabiana Perrone, Matteo Puntoni, et al.
The Oncologist|December 24, 2025
Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥50%: real-world data from the italian ATLAS registryFrancesco Passiglia, Maria Lucia Reale, Giulia Pasello, et al.
Pageof 10